Geron reiterates 2026 RYTELO net product revenue guidance of $220 million-$240 million
GERN•Geron reiterated its 2026 RYTELO net product revenue guidance of $220 million-$240 million and projected operating expenses of $230 million-$240 million. Second-quarter RYTELO revenue rose 17% year over year, while demand volume increased 5% sequentially.
1. Revenue outlook
Geron said it continues to expect 2026 RYTELO net product revenue of $220 million-$240 million, with total operating expenses projected at $230 million-$240 million. RYTELO net product revenue rose 17% year over year in the second quarter, and demand volume increased 5% sequentially.
2. Trial and strategy
Geron discontinued its imetelstat IMpactMF trial in relapsed or refractory myelofibrosis in October 2026. The company plans to communicate RYTELO's European commercial strategy for lower-risk myelodysplastic syndromes by the end of 2026.
